Q-omics provides the consensus-scored INSYN2A profile across patient tissues and cancer cell-line models. INSYN2A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, INSYN2A is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, INSYN2A RNA expression shows 16,966 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where INSYN2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INSYN2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INSYN2A survival associations across molecular data types. INSYN2A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INSYN2A RNA expression–survival associations across cancer types. High INSYN2A expression shows unfavorable associations in UVM, UCEC, ACC, LAML and LIHC, but favorable associations in HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for INSYN2A RNA expression.
This table summarizes INSYN2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for INSYN2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INSYN2A shows lower tumor expression in KIRC and KIRP and higher tumor expression in LIHC, BRCA, LUAD and THCA. The KIRC box plot shows higher INSYN2A RNA expression in normal versus tumor tissue (log2 FC = −0.421, t-test p < 0.001).
This table shows molecular features associated with INSYN2A in patient tissues and cancer cell lines. In patient samples, INSYN2A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, INSYN2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
